Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. Paper › Research › Not peer-reviewed
  2. Published

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conferencePaper

  3. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conferencePaper

  4. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conferencePaper

  5. Published

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.

    Research output: Contribution to conferencePaper

  6. Published

    Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Aug 2007.

    Research output: Contribution to conferencePaper

  7. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conferencePaper

  8. Published

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conferencePaper

  9. Published

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Jun 2008.

    Research output: Contribution to conferencePaper

  10. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conferencePaper

  11. Published

    Economic evaluation of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Jan 2009.

    Research output: Contribution to conferencePaper